Nuformix PLC
NFX
Company Profile
Business description
Nuformix PLC is a pharmaceutical development company. It operates in pharmaceutical development, targeting unmet medical needs in fibrosis and oncology through drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.
Contact
C/O Arch Law Limited
8 Bishopsgate
Huckletree Bishopsgate
LondonEC2N 4BQ
GBRT: +44 3332423976
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2026
Employees
3
Stocks News & Analysis
stocks
Undervalued REIT receives offer from PE firm
Our analysts’ view on the value of the unsolicited offer.
stocks
Apple: With launch of foldable iPhone duo things look twice as nice
We’ve raised our fair value estimate of Apple stock.
stocks
What did Morningstar subscribers buy and sell during August?
Earnings season fuels trading activity.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,920.20 | 13.80 | 0.15% |
| CAC 40 | 8,179.77 | 63.01 | 0.78% |
| DAX 40 | 25,568.56 | 207.41 | 0.82% |
| Dow JONES (US) | 52,573.29 | 509.19 | 0.98% |
| FTSE 100 | 10,650.44 | 41.52 | 0.39% |
| HKSE | 24,805.63 | 148.84 | -0.60% |
| NASDAQ | 26,333.04 | 251.31 | 0.96% |
| Nikkei 225 | 64,011.34 | 1,259.61 | -1.93% |
| NZX 50 Index | 13,580.33 | 130.68 | -0.95% |
| S&P 500 | 7,656.98 | 65.28 | 0.86% |
| S&P/ASX 200 | 8,741.20 | 23.30 | 0.27% |
| SSE Composite Index | 3,888.11 | 46.29 | -1.18% |